Ultimately, it has to be emphasized that the interplay between CRC cellular resistance and the PXR nuclear factor minimizes the treatment response to Irinotecan, which is a DNA topoisomerase I inhibitor class of anti-neoplastic drugs for several solid tumors, including CRC. Here, NR1I2 is linked to colorectal carcinoma.